Benjamin Makamson, MD
Vascular Surgery · Mobile, ALNPI 1518960038
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 23.7%. Reporting peaked in 2019 at $6,494 and has fallen 91.2% since, to $571 in 2025.
Across 196 payments — averaging $89.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$4K
- Siemens Medical Solutions USA, Inc.$4K
- Globus Medical$2K
- Organogenesis Inc.$2K
- Penumbra, Inc.$1K
- Medtronic$626
- plus $3K from 31 others
What the payments were for
- Consulting fees$2,00011%
- Speaking & faculty fees$4,40025%
- Travel & lodging$3,22518%
- Food & beverage$7,98145%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 38 | $4,166 |
| Siemens Medical Solutions USA, Inc. | 6 | $4,111 |
| Globus Medical | 4 | $2,403 |
| Organogenesis Inc. | 8 | $1,814 |
| Penumbra, Inc. | 22 | $1,259 |
| Medtronic(2 entities) | 15 | $626 |
| Philips North America LLC | 6 | $416 |
| Bard Peripheral Vascular, Inc. | 7 | $368 |
| Terumo Medical Corporation | 4 | $361 |
| Johnson & Johnson | 17 | $239 |
| Stryker | 6 | $221 |
| Boston Scientific | 8 | $219 |
| Cook Medical LLC | 8 | $189 |
| Cordis US CORP. | 2 | $146 |
| Veryan Medical Incorporated | 2 | $144 |
| Abbott | 8 | $141 |
| Smith+Nephew | 4 | $126 |
| W. L. Gore & Associates, Inc. | 3 | $83 |
| Teleflex LLC | 2 | $70 |
| Angiodynamics, Inc. | 3 | $56 |
| Vifor Pharma, Inc. | 3 | $50 |
| Tactile Systems Technology Inc | 2 | $47 |
| Baxter Healthcare | 1 | $45 |
| Amgen | 2 | $42 |
| Triad Life Sciences Inc. | 1 | $36 |
| Lemaitre Vascular, Inc. | 2 | $35 |
| Biocompatibles, Inc. | 2 | $26 |
| Davol Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Kerecis Limited | 1 | $19 |
| CSL Behring | 1 | $19 |
| KCI USA, Inc. | 1 | $18 |
| Inari Medical, Inc. | 1 | $18 |
| Bioventus LLC | 1 | $16 |
| Endologix LLC | 1 | $11 |
| Acera Surgical, Inc. | 1 | $11 |
| Medela LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Peripheral Orbital Atherectomy System$3,317
- CORBEL$2,398
- PuraPly$1,661
- ENDURANT IIS$341
- Indigo System$326
- CLOTTRIEVER BOLD CATHETER$164
- Diamondback Peripheral$162
- Puraply Antimicrobial$123
- BioMimics 3D Vascular Stent System$116
- RUBY Coil$113
- S.M.A.R.T.$103
- METACROSS OTW$102
How this compares
$17,606 in reported general payments places this provider in the 80th percentile of 61 vascular surgery providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 43 | $36,486 |
| EliquisApixaban | 11 | $6,435 |
| ClopidogrelClopidogrel Bisulfate | 140 | $1,562 |
| Doxycycline Hyclate | 16 | $138 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $116 |
| Atorvastatin Calcium | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $239 | $36,48643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 61 vascular surgery providers in Alabama.
Other vascular surgery in Mobile
- Mina JacobMobile$19K
- Lee FergusonMobile$13K
- Cullen McCarthyMobile$8K
- Glenn EssesMobile$7K
- Michael DoMobile$7K
- Lewis LyonsMobile$6K
- William HardyMobile$3K
- Melanie RoseMobile$3K
- Ralph PfeifferMobile$2K
- Albert PacificoBirmingham$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.